[Modification of hemorheologic parameters by beta-receptor blockers with special reference to propranolol and talinolol].
There are no systematic and complex investigations regarding the hemorheologic action of the betablockers propranolol and talinolol. The results on the other ones are contradictory. On the basis of a critical survey of the literature, in-vitro-experiments and studies in animals (rats) and humans may conclude that there are no remarkable deteriorations of rheological parameters in the therapeutic dose range. This is valid for diseases only where the haemodynamic regulation doesn't prevail.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects; D001809:Blood Viscosity / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004907:Erythrocyte Deformability / Q000187:drug effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use*; D051381:Rats
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C011550:talinolol; D011433:Propranolol
Zur Beeinflussung hämorrheologischer Parameter durch beta-Rezeptorenblocker unter spezieller Berücksichtigung von Propranolol und Talinolol.